Nuformix PLC Appointment of Dr Dan Gooding as Consultant
March 02 2022 - 2:01AM
RNS Non-Regulatory
TIDMNFX
Nuformix PLC
02 March 2022
REACH
2 March 2022
Nuformix plc
("Nuformix" or the "Company")
Appointment of Dr Dan Gooding as Consultant
Nuformix plc (LSE: NFX), the pharmaceutical development company
targeting unmet medical needs in fibrosis and oncology via drug
repurposing, is pleased to announce the appointment of Dr Dan
Gooding as a consultant to the Company. Dr Gooding was a co-founder
and ex-CEO of Nuformix and instigated the Company's NXP002
programme as an inhaled therapy for the treatment of Idiopathic
Pulmonary Fibrosis ("IPF").
Commenting on his appointment, Dr Gooding said: " I am a strong
believer in the potential of NXP002 as an inhaled therapy for the
treatment of IPF. The recent positive pre-clinical data further
cements this belief and I am delighted to be able to support the
Company in its development and commercialisation activities for the
NXP002 programme. My detailed knowledge of previous development
strategies, commercial discussions and continued commitment to the
success of the project and the Company will now be brought to bear
in a formal way, alongside the Nuformix team, for the benefit of
the NXP002 programme and the Company's shareholders."
Nuformix's Executive Chairman, Dr Alastair Riddell, said : " The
recent positive pre-clinical studies on NXP002 warrant the
progression of further product development and commercial
discussions with licensing partners. Dr Gooding brings significant
corporate history and experience to the table which will help
facilitate these activities.
"Now the Company is able to invest in the formal development of
NXP002, our objective is to progress NXP002 through a series of
value-inflexion points prior to out-licensing. We look forward to
announcing further results from our ongoing pre-clinical studies on
NXP002 in the near future.
"Furthermore, our search for a new CEO is progressing well and I
look forward to announcing an appointment in due course."
Enquiries:
Nuformix plc
Dr Alastair Riddell, Executive Chairman Via IFC Advisory
Stanford Capital Partners Limited
Tom Price / Patrick Claridge (Corporate
Finance) +44 (0) 20 3650 3650
John Howes (Corporate Broking) +44 (0) 20 3650 3652
IFC Advisory Limited
Tim Metcalfe +44 (0) 20 3934 6630
Zach Cohen nuformix@investor-focus.co.uk
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing. The
Company aims to use its expertise in discovering, developing and
patenting novel drug forms, with improved physical properties, to
develop new products in new indications that are, importantly,
differentiated from the original (by way of dosage, delivery route
or presentation), thus creating new and attractive commercial
opportunities. Nuformix has an early-stage pipeline of preclinical
and Phase 1-ready assets with potential for significant value and
early licensing opportunities.
About NXP002
NXP002 is a new form of tranilast being developed as an inhaled
product for the treatment of Idiopathic Pulmonary Fibrosis, a
devastating lung disease with a high mortality rate. The IPF market
reached a value of GBP2bn in 2021 and is forecast to grow to
GBP6.6bn by 2027. Novel therapeutic interventions are required as
approved therapies are limited to slowing disease progression.
NXP002 is being developed for delivery direct to the lungs by
inhalation, a new route of administration for this drug, uniquely
enabled by Nuformix technology protected by internationally granted
patents. The inhalation route is a well-known strategy for
treatment of lung diseases to yield greater efficacy and reduce
systemic side-effects compared to oral treatment.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRABIGDXGXGDGDB
(END) Dow Jones Newswires
March 02, 2022 02:01 ET (07:01 GMT)
Nuformix (LSE:NFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nuformix (LSE:NFX)
Historical Stock Chart
From Jul 2023 to Jul 2024